PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
27055598-8	2016	DETD-35 significantly suppressed metastatic pulmonary foci information along with the expression level of VEGF and COX-2 in SCID mice.	detd-35	0-7	vascular endothelial growth factor A	Mus musculus	106-110
27055598-8	2016	DETD-35 significantly suppressed metastatic pulmonary foci information along with the expression level of VEGF and COX-2 in SCID mice.	detd-35	0-7	cytochrome c oxidase II, mitochondrial	Mus musculus	115-120
33810045-8	2021	Most importantly, DET and DETD-35 inhibited lung metastasis of A375LM5IF4g/Luc in NOD/SCID mice through inhibiting pulmonary vascular permeability and melanoma cell (Mel-A+) proliferation, angiogenesis (VEGF+, CD31+) and EMT (N-cadherin) in the tumor microenvironment in the lungs.	detd-35	26-33	melanoma antigen	Mus musculus	166-171
33810045-8	2021	Most importantly, DET and DETD-35 inhibited lung metastasis of A375LM5IF4g/Luc in NOD/SCID mice through inhibiting pulmonary vascular permeability and melanoma cell (Mel-A+) proliferation, angiogenesis (VEGF+, CD31+) and EMT (N-cadherin) in the tumor microenvironment in the lungs.	detd-35	26-33	vascular endothelial growth factor A	Mus musculus	203-207
33810045-8	2021	Most importantly, DET and DETD-35 inhibited lung metastasis of A375LM5IF4g/Luc in NOD/SCID mice through inhibiting pulmonary vascular permeability and melanoma cell (Mel-A+) proliferation, angiogenesis (VEGF+, CD31+) and EMT (N-cadherin) in the tumor microenvironment in the lungs.	detd-35	26-33	platelet/endothelial cell adhesion molecule 1	Mus musculus	210-214
33810045-8	2021	Most importantly, DET and DETD-35 inhibited lung metastasis of A375LM5IF4g/Luc in NOD/SCID mice through inhibiting pulmonary vascular permeability and melanoma cell (Mel-A+) proliferation, angiogenesis (VEGF+, CD31+) and EMT (N-cadherin) in the tumor microenvironment in the lungs.	detd-35	26-33	cadherin 2	Mus musculus	226-236
35231572-5	2022	We discovered that DET and DETD-35 are a new type of GPX4 enzyme inhibitor through non-covalent binding.	detd-35	27-34	glutathione peroxidase 4	Homo sapiens	53-57
28915644-7	2017	Further, knockdown of MEK upstream regulator RAF1 and autophagosomal marker LC3, and co-treatment with JNK or ERK1/2 inhibitor resulted in the most significant attenuation of DETD-35-induced morphological and molecular or biochemical changes in cancer cells, while the inhibitory effect of DET was not influenced by MAPK inhibitor treatment.	detd-35	175-182	mitogen-activated protein kinase kinase 7	Homo sapiens	22-25
28915644-7	2017	Further, knockdown of MEK upstream regulator RAF1 and autophagosomal marker LC3, and co-treatment with JNK or ERK1/2 inhibitor resulted in the most significant attenuation of DETD-35-induced morphological and molecular or biochemical changes in cancer cells, while the inhibitory effect of DET was not influenced by MAPK inhibitor treatment.	detd-35	175-182	Raf-1 proto-oncogene, serine/threonine kinase	Homo sapiens	45-49
28915644-7	2017	Further, knockdown of MEK upstream regulator RAF1 and autophagosomal marker LC3, and co-treatment with JNK or ERK1/2 inhibitor resulted in the most significant attenuation of DETD-35-induced morphological and molecular or biochemical changes in cancer cells, while the inhibitory effect of DET was not influenced by MAPK inhibitor treatment.	detd-35	175-182	mitogen-activated protein kinase 8	Homo sapiens	103-106
28915644-7	2017	Further, knockdown of MEK upstream regulator RAF1 and autophagosomal marker LC3, and co-treatment with JNK or ERK1/2 inhibitor resulted in the most significant attenuation of DETD-35-induced morphological and molecular or biochemical changes in cancer cells, while the inhibitory effect of DET was not influenced by MAPK inhibitor treatment.	detd-35	175-182	mitogen-activated protein kinase 3	Homo sapiens	110-116